News | December 06, 2023
Sun Pharmaceutical inks licensing agreement with Aclaris Therapeutics
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Subscribe To Our Newsletter & Stay Updated
